Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03697850 2025-11-18

BladderSpar

Phase 2 Active not recruiting

79 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Phase 2 Active not recruiting

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

63 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02662309 2025-03-10

ABACUS

Phase 2 Completed

96 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03799835 2024-12-11

ALBAN

Phase 3 Active not recruiting

517 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04289779 2024-12-04

ABATE

Phase 2 Active not recruiting

46 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05259319 2023-10-17

IMMUNOs-SBRT

Phase 1 Unknown

92 enrolled

GenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04186013 2022-10-26

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Phase 2 Active not recruiting

39 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2 Active not recruiting

21 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Clinical Trials

TOMBOLA

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

BladderSpar

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

ABACUS

ALBAN

ABATE

IMMUNOs-SBRT

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma